spacer
home > ict > autumn 2018 > modifying methods
PUBLICATIONS
International Clinical Trials

Modifying Methods

ICT: Why has there recently been more interest in adaptive trials?

Dr Sy Pretorius: The UK government announcing a 40 million investment in the Dame Tessa Jowell Brain Cancer Research Mission which includes speeding up the use of adaptive trials to test different treatments at the same time and streamlining the process has shed a new spotlight of media interest on the topic, but several reasons exist for this for broader increased interest as well.

For one, regulatory agencies especially the FDA in the US and EMA in Europe are encouraging the use of adaptive trials. Both of these agencies have been supportive in terms of their comments around the use of the adaptive designs where appropriate. Additionally, several recent statistical and technological advancements have made these trials more viable.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Sy Pretorius MD leads Medical and Scientific Services at PAREXEL. In this role, Sy collaborates with biopharmaceutical and medical device clients in designing and optimising drug/device development strategies and plans, as well as finding, evaluating, and purchasing assets. He is passionate about drug development, leading several initiatives on clinical trial innovation. Sy is a medical doctor with Master's degrees in clinical pharmacology, business administration, and the management of drug development.
spacer
Dr Sy Pretorius
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

HemaCare and Tissue Solutions Announce Strategic Partnership to Expand Access to Human Disease-State Samples

HemaCare Corporation (OTCMKTS: HEMA), a global leader and trusted brand in the customization of human-derived biological products and services for biomedical research, drug discovery, and cellular therapy process development, and Tissue Solutions Ltd, a leading global provider of diseased human biosamples for research, today announced their partnership to supply customers with an expanded selection of well-qualified disease-state biomaterials in fresh, frozen, and FFPE formats.
More info >>

White Papers

Quality By Design

Biopharma Group

Quality by Design (QbD) is a systematic approach to development that begins with the defined objectives and emphasizes science and quality risk management in order to achieve those goals. QbD ensures that the quality of the product is built into production processes from the outset, rather than being tested after development has already commenced.
More info >>

 
Industry Events

World Advanced Therapies & Regenerative Medicine Congress 2019

15-17 May 2019, Business Design Centre, London

The World Advanced Therapies & Regenerative Medicine Congress is an exhibition and conference that has grown to become one of the best and most established cell and gene events in the world today.     The 2019 edition will be in its 14th year and it continues to grow and attract a large audience of biotech, pharma, start-ups, investors, research and technology companies from around the world. The conference and exhibition will host over 1000 attendees, 250 speakers and 80 exhibition booths. Over 500 different global companies are represented every year at this event. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement